Archives: Speakers

Dr Mishra (Ex Genentech, Ex NCI, Ex NIH) is the founding president and CEO of the American Association for Precision Medicine ( and chair of ACT AAPM’s Coronavirus Taskforce He is leading research efforts focused on preventing curing chronic diseases not only treating the sick but also providing knowledge/tools to individuals to live longer, healthier lives

He is also the founder and CEO of Agility Pharmaceuticals, a pharmaceutical company committed to revolutionizing drug discovery development through technology, big data, robotics, and artificial intelligence He is a serial entrepreneur who founded his first company after graduating high school, and his second company during his Ph D Since then, he has accumulated a wealth of experience by building, investing, and advising numerous other companies He is an investor, co founder/ board member of a few corporations, focused on accelerating drug discovery/ development, data analytics, robotics, mental health, and digital health He is also the founder of AAPM Angels and Investors AAi an investment group focused on investing in drug discovery, diagnostics, precision medicine, technology healthcare companies He is also the founding investor and advisor to Barcelona Ventures and serves as an advisor to a 100 M private equity fund

Widely recognized as a thought leader in the field of ‘technology and healthcare’, Dr Mishra has keynoted, chaired, curated, and organized numerous successful international conferences He served as a Scientist and Principal Investigator at the pharma giant Genentech, Roche Where he participated in several drug discovery project teams Moreover, his passion for drug development and precision medicine has led to the identification of new drug targets, biomarkers, companion diagnostics, and several drugs/ combinations in the clinic

His research work has been recognized globally by over 40 prestigious awards and honors Due to his unique perspective selfless service, he is a highly respected sought after mentor to many The companies that he has advised have raised multimillion dollars Notably, he serves as a mentor and advisor to several VC funds and startup accelerators, including IndieBio HIMSS/Health 2 0 ’s Project Zygote, MedLabs ZGC Capital, J&J JLabs UCSF Innovation Venture, UCSF Invent Fund, and California Life Sciences’s FAST program, to help grow California’s life sciences innovation ecosystem

Thiago Favano serves as Senior Director, Program Operations, leading MiNK’s clinical operations and portfolio strategy. Over 17 years of extensive experience across clinical development and operations, clinical research, market access, project management and strategic business projects on a global scale. with a remarkable ability to navigate complex regulatory landscapes and drive operational efficiency. He previously served as Senior Director of Clinical Development and Operations, and Senior Strategic Advisor for Orphan DC. He also served various positions in the Pharmaceutical industry, including Clinical Operations Consultant at Atea Pharmaceuticals, and roles at Alexion Pharmaceuticals. He is fluent in English, Spanish, French, and Portuguese, and received a PharmD and MBA from Universities in Brazil.

礼新医药临床运营副总裁。曾在精鼎、方恩等CRO公司任职并负责方恩临床运营工作，此后在罗氏以及珐博进、华领、康宁杰瑞等Biotech企业担任临床运营部门负责人，负责多项国际国内研究，并助力多项1.1类新药成功获批。

Paul Kong, leads Clinical Operation team within LaNova since Apr, 2021. He has more than 10 years experiences in CRO, such as Parexel and FMD, and then taking the leading role from various biotechs and big pharm, Roche, FibroGen, Hua Medicine and Alphamab in clinical operation team; and he has major contributions for lots of first in class production registration.

肖申博士现任礼邦制药首席科学官，负责公司新药的临床前开发和全球药物注册，并协同首席医学官推进公司新药的临床开发工作。之前曾任海森生物医药有限公司首席医学官，思路迪医药的首席战略官和首席医学官。肖申博士曾在美国食品药物监督管理局（FDA）担任药理,毒理的非临床高级审评员负责内分泌，代谢疾病新药的非临床审评，和临床高级审评员负责心、肾、血管疾病新药的临床审评。在近二十年的 FDA工作生涯中，负责审评了数百个新药开发（IND）的各个阶段，跨度从临床前期、临床各期、及上市后的药物疗效、安全跟踪、随访；做为临床评审员和/或综合评审小组负责人负责审批了十几个新药的上市工作。其间曾在 FDA 医疗器械审评中心（CDRH），负责多个相关医疗设备的审评、审批（IDE，510k，PMA）。​

加入 FDA 之前，曾作为内科临床主治医生、博士研究助理和博士后有十多年的临床工作和实验室研究经验，包括各类普通内科疾病诊治、抗生素临床药代动力学的研究、细胞信号传导的研究等。其间除了曾获国家科技进步三等奖一项，全军科技进步二等奖一项外，还获得 FDA，美国生理协会（APS），国际肾脏病协会（ISN），日本透析和人工脏器协会的多项奖励。​

Be responsible for the setting of company’s R/D product pipelines, non-clinical and clinical product development, and global regulatory affairs. Previously, he served as the Chief Medical Officer at Hasten Biopharmaceutical Co, Ltd, and the Chief Medical Officer and Chief Strategy Officer at 3D Medicines Inc for taking the full responsibilities of company’s clinical product development and global regulatory affairs.  

Before that, Dr. Xiao worked in the US FDA as a senior medical officer and was responsible for the clinical review of new drugs in the areas of Cardiovascular, renal, diabetes, obesity and some other endocrine and metabolic diseases. During his nearly 20-year career at the FDA, he reviewed several hundreds of Investigational New Drug (IND) applications across various stages, including preclinical, clinical phases, and post-marketing drug efficacy and safety tracking, and follow-up. As a clinical reviewer and/or multiple discipline team leader, he approved over a dozen of NDAs/BLAs. He also worked at the FDA’s Center for Devices and Radiological Health (CDRH), where he reviewed and approved multiple medical devices (IDE, 510K, PMA). 

Prior to FDA, as an attending physician in Nephrology in China and research fellow in US, he had over a decade of clinical practice and laboratory research experience. His experience includes diagnosing and treating a variety of general internal medicine diseases, renal diseases, conducting the clinical pharmacokinetics studies for different antibiotics, and studying cell signaling pathways. During this time, he was awarded numerous honors including the China National Scientific and Technological Third Award,  and many other awards from the FDA, the American Physiological Society (APS), the International Society of Nephrology (ISN), and the Japanese Society for Dialysis Therapy and Artificial Organs (JSDAO).